Physician profile
Geneva E Daneker
NPI 1619419157
$883.00
in general payments reported to CMS, 2019-2025
12 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $92.59 · 2023: $246 · 2024: $187 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192.73 | 2021-2025 | |
| Janssen Biotech, INC. | $180.79 | 2022-2025 | Tremfya, Simponi, Remicade |
| Allergan, INC. | $126.38 | 2021-2022 | |
| Genzyme Corporation | $96.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $73.81 | 2021-2025 | |
| Lilly USA, LLC | $43.82 | 2021-2025 | Ebglyss |
| Sun Pharmaceutical Industries INC. | $41.64 | 2024 | |
| Integra Lifesciences Corporation | $32.93 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| E.R. Squibb & Sons, L.L.C. | $31.02 | 2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $26.59 | 2025 | Libtayo |
| Leo Pharma INC. | $22.70 | 2025 | Anzupgo |
| Incyte Corporation | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geneva Daneker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.